Features Of The Immunity T-System In Patients With Glomerulonephritis With Nephrotic Syndrome
Keywords:
glomerulonephritis, nephrotic syndrome, T-lymphocytes, T-regulatory cells, subpopulation of T-lymphocytes.Abstract
The study of issues related to glomerulonephritis with nephrotic syndrome is one of the pressing problems of medicine due to their prevalence throughout the world, mainly in the young age group. There are primary (idiopathic) nephrotic syndrome, which occurs in 80-90% of cases, and secondary nephrotic syndrome, associated primarily with systemic autoimmune diseases, diabetes mellitus and neoplasms. It is known that glomerulonephritis, manifested by nephrotic syndrome (membranous nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy), are autoimmune diseases. To date, the immunological mechanisms of the pathogenesis of glomerulonephritis with nephrotic syndrome associated with the T-system of adaptive immunity remain unexplored.
References
Bajnok A., Ivanova M., Rigo J., Jr., Toldi G. The Distribution of Activation Markers and Selectins on Peripheral T Lymphocytes in Preeclampsia. Mediators Inflamm., 2017, vol. 2017, e8045161. DOI: 10.1155/2017/8045161.
Boumedien A., Vachin P., Sendeyo K. et al. NEPHRUTIX: A randomized, double-blind, placebo vs. Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.
J. Autoimmun., 2018, vol. 88, pp. 91–102. DOI: 10.1016/j.jaut.2017.10.006. 3. Campbell RE, Thurman JM The Immune System and Idiopathic Nephrotic Syndrome. Clin. J.
Am. Soc. Nephrol.,2022, vol. 17, pp. 1823–1834. DOI: 10.2215/CJN.07180622. 4. Chen M., Liu J., Xiong Y., Xu G. Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis. Int. J. Clin. Pract., 2022, vol. 2022, e4996239. DOI: 10.1155/2022/4996239.
Colucci M., Oniszczuk J., Vivarelli M., Audard V. B-Cell Dysregulation in Idiopathic Nephrotic
Syndrome: What We Know and What We Need to Discover. Front. Immunol., 2022, vol. 13, e823204.
DOI: 10.3389/fimmu.2022.823204. 6. Dall'Era M., Pauli M.L., Remedios K. et al. Autoimmunity Centers of Excellence. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol., 2019, vol. 71(3), pp. 431–440. DOI: 10.1002/art.40737.
Fervenza FC, Appel GB, Barbour SJ et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N.Engl. J. Med., 2019, vol. 381(1), pp. 36–46. DOI: 10.1056/NEJMoa1814427.
Go AS, Tan TC, Chertow GM et al. Primary nephrotic syndrome and risks of ESKD, cardio-vascular events, and death: the Kaiser Permanente nephrotic syndrome study. J. Am. Soc. Nephrol., 2021, vol. 32, pp. 2303–2314. DOI: 10.1681/ASN.2020111583.
Hu R., Quan S., Wang Y. et al. Spectrum of biopsy proven renal diseases in central China: A 10-year retrospective study based on 34,630 cases. Sci. Rep., 2020, vol. 10, e10994. DOI: 10.1038/s41598-020-67910-w.
Jarnicki AG, Lysaght J., Todryk S., Mills KH Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells . J. Immunol., 2006, vol. 177(2), pp. 896–904. DOI: 10.4049/jimmunol.177.2.896.
Kemper MJ, Zepf K, Klaassen I et al. Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am J. Nephrol., 2005, vol. 25(2), pp. 132–137. DOI: 10.1159/000085357.
Khandelwal P., Chaturvedi V., Owsley E. et al. CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Biol. Blood Marrow Transplant., 2020, vol. 26(1), pp. 1–6. DOI: 10.1016/j.bbmt.2019.08.008.
Clinical researches17
URL: http://acta-medica-eurasica.ru/single/2024/1
13. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group.
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int., 2021, vol. 100(4S), S1–S276. DOI: 10.1016/j.kint.2021.05.021.
Kumar P., Saini S., Khan S. et al. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. Cell Immunol., 2019, vol. 339, pp. 41–49. DOI: 10.1016/j.cellimm.2018.09.008.
Kuroki A., Iyoda M., Shibata T., Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int., 2005, vol. 68(1), pp. 302–310. DOI: 10.1111/j.1523-1755.2005.00415.x.
Lama G., Luongo I., Tirino G. et al. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am. J. Kidney Dis., 2002, vol. 39(5), pp. 958–965. DOI: 10.1053/ajkd.2002.32769.
Ma DH, Yang XD, Hua QJ et al. Changes and significance of Treg and Th17 in adult patients with primary membranous nephropathy. Clin. Nephrol., 2021, vol. 96(3), pp. 155–164. DOI: 10.5414/CN110333.
Motavalli R., Etemadi J., Kahroba H. et al. Immune system-mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets. Life Sci., 2019, vol. 238, e116923. DOI: 10.1016/j.lfs.2019.116923.
Motavalli R, Etemadi J, Soltani-Zangbar MS et al. Altered Th17/Treg ratio as a possible mech-anism in pathogenesis of idiopathic membranous nephropathy. Cytokine, 2021, vol. 141, e155452. DOI: 10.1016/j.cyto.2021.155452.
Pal A., Kaskel F. History of nephrotic syndrome and evolution of its treatment. Front. Pediatr., 2016, vol. 4, p. 56. DOI: 10.3389/fped.2016.00056.
Piedra-Quintero ZL, Wilson Z., Nava P., Guerau-de-Arellano M. CD38: An Immunomodulatory
Molecule in Inflammation and Autoimmunity. Front. Immunol., 2020, vol. 30(11), e597959. DOI: 10.3389/- fimmu.2020.597959
Ponticelli C., Praga M., Moroni G. Calcineurin Inhibitors in Membranous Nephropathy. Kidney Int. Rep., 2021, vol. 6(10), pp. 2537–2539. DOI: 10.1016/j.ekir.2021.08.008.
Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Dis- ease in Children. Kidney Int., 1981, vol. 20, pp. 765–771. DOI: 10.1038/ki.1981.209.
Richards NT, Darby S, Howie AJ et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol. Dial. Transplant., 1994, vol. 9(9), pp. 1255–1259
Sakaguchi S. Taking regulatory T cells into medicine. J. Exp. Med., 2021, vol. 218(6), e20210831. DOI: 10.1084/jem.20210831.
Salfi G., Casiraghi F., Remuzzi G. Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis. Front. Immunol., 2023, vol. 14, e1247606. DOI: 10.3389/fimmu.2023.1247606.
So L., Obata-Ninomiya K., Hu A. et al. Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis. J. Exp. Med., 2023, vol. 220(3), e20221676. DOI: 10.1084/jem.20221676.
Tsuji S., Akagawa S., Akagawa Y. et al. Idiopathic nephrotic syndrome in children: role of regulatory T cells and gut microbiota. Pediatr. Res., 2021, vol. 89(5), pp. 1185–1191. DOI: 10.1038/s41390-020-1022-3.
29. Vivarelli M., Massella L., Ruggiero B., Emma F.Minimal change disease. Clin. J. Am. Soc.
Nephrol,2017, vol. 12, pp. 332–345. DOI: 10.2215/CJN.05000516.
